SAR441169

SAR441169 is a small molecule drug developed as an inverse agonist of the nuclear hormone receptor RORγt (retinoic acid receptor-related orphan receptor gamma t). It was designed to modulate the interleukin-17 inflammatory pathway, which plays a critical role in chronic autoimmune diseases such as psoriasis. The drug was initially developed by Lead Pharma and later co-developed with Sanofi. Its primary indication was for the treatment of psoriasis, aiming to provide an oral alternative to injectable biologics targeting similar pathways. Clinical development reached Phase 1 trials but has since been discontinued for psoriasis[1][2][3][4].

Other names

Retinoid orphan receptor gamma t inhibitorROR gamma t inhibitor